Results 61 to 70 of about 10,402 (207)

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

BMC Cancer, 2006
Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian ...
D'Arco Alfonso, Musso Pietro, Ferro Antonella, Naglieri Emanuele, Del Gaizo Filomena, Natale Donato, Gebbia Vittorio, Rossi Emanuela, De Vivo Rocco, Scollo Paolo, Breda Enrico, Savarese Antonella, Scambia Giovanni, Pignata Sandro, Sorio Roberto, Pisano Carmela, Di Maio Massimo, Signoriello Giuseppe, Annunziata Annalisa, Perrone Francesco   +19 more
doaj   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Skin problems associated with pegylated liposomal doxorubicin-more than palmoplantar erythrodysesthesia syndrome [PDF]

, 2008
Liposomal pegylated doxorubicin is an encapsulation form of doxorubicin, with an improved pharmacokinetic profile and the ability to selectively accumulate into tumor tissue.
Knuth, Alexander, Knuth, A., Oberholzer, P.A., Mangana, J., Oberholzer, Patrick A, Cozzio, Antonio, Zipser, M.C., Dummer, R., Dummer, Reinhard; https://orcid.org/, Zipser, Marie C, Conrad, C., Cozzio, A., French, L.E., Conrad, Curdin, Mangana, Joanna, French, Lars E; https://orcid.org/   +15 more
core   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Clinical Trials with Pegylated Liposomal Doxorubicin in the Treatment of Ovarian Cancer [PDF]

Journal of Drug Delivery, 2013
Among the pharmaceutical options available for treatment of ovarian cancer, increasing attention has been progressively focused on pegylated liposomal doxorubicin (PLD), whose unique formulation prolongs the persistence of the drug in the circulation and potentiates intratumor accumulation.
Pisano, Carmela, Cecere, Sabrina Chiara, Di Napoli, Marilena, Cavaliere, Carla, Tambaro, Rosa, Facchini, Gaetano, Scaffa, Cono, Losito, Simona, Pizzolorusso, Antonio, Pignata, Sandro   +9 more
openaire   +2 more sources

Pharmacokinetics and biodistribution of 2B3-101, pegylated liposomal doxorubicin and free doxorubicin in mice.

, 2014
Healthy mice (n = 5–6 per group) received 1 dose (5 mg/kg) 2B3-101, pegylated liposomal doxorubicin (PEG-lipo-DOX) or free doxorubicin (free DOX). (A) The pharmacokinetic profile shows a higher exposure for 2B3-101 and pegylated liposomal doxorubicin ...
Pieter J. Gaillard (506968), Francesca Manca (506972), Guus A. M. S. van Dongen (506975), Rick Dorland (506970), Bert Windhorst (506974), Danielle J. Vugts (506973), David Maussang (120639), Joan van Kregten (506971), Chantal C. M. Appeldoorn (506969), Olaf van Tellingen (135587), Helga E. de Vries (256441)   +10 more
core   +1 more source

Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study

, 2023
Objective Poly (ADP-ribose) polymerase (PARP) inhibitor resistance is problematic in epithelial ovarian cancer management and sequencing strategies may be performed to overcome this issue.
Avesani, Giacomo, Scambia, Giovanni, Fagotti, Anna, Corrado, Giacomo, Marchetti, Claudia   +4 more
core   +1 more source

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

BMC Medicine, 2019
Background The Opti-HER HEART trial aimed to optimize activity while minimizing cardiac risk by combining trastuzumab, pertuzumab, and paclitaxel with non-pegylated liposomal doxorubicin in the treatment of HER2-positive early breast cancer.
Joaquín Gavilá, Mafalda Oliveira, Tomás Pascual, Jose Perez-Garcia, Xavier Gonzàlez, Jordi Canes, Laia Paré, Isabel Calvo, Eva Ciruelos, Montserrat Muñoz, Juan A. Virizuela, Isabel Ruiz, Raquel Andrés, Antonia Perelló, Jerónimo Martínez, Serafín Morales, Mercedes Marín-Aguilera, Débora Martínez, Juan C. Quero, Antonio Llombart-Cussac, Aleix Prat   +20 more
doaj   +1 more source

Hypersensitivity to Excipients in Drugs: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Drugs contain active pharmaceutical ingredients and excipients, compounds which enhance the pharmacokinetics, stability and palatability of the pharmaceutical formulation. While most drug hypersensitivity reactions (DHR) are caused by active ingredients, excipients may also be involved.
Lene H. Garvey, Knut Brockow, Annick Barbaud, Charlotte G. Mortz, Gianfranco Calogiuri, Asli Gelincik, Osman O. Yeğit, Alla Nakonechna, Annette Wagner, Rik Schrijvers, Toon Ieven   +10 more
wiley   +1 more source

Non-Pegylated Liposomal Doxorubicin in Combination with Cyclophosphamide or Docetaxel as First-Line Therapy in Metastatic Breast Cancer: A Retrospective Analysis

, 2009
Aims and background Anthracyclines such as doxorubicin play a central role in the management of advanced breast cancer. Unfortunately, the clinical benefits of anthracyclines are limited by cardiotoxicity that can lead to the development of potentially ...
Alessia Petrucci, Daniela Greto, Carla De Luca Cardillo, Lorenzo Livi, Giampaolo Biti, Icro Meattini, Andrea Rampini, Luigi Cataliotti, Monica Mangoni, Alessio Bruni, Alessandra Galardi   +10 more
core   +2 more sources